Skip to content

Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia

Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00899587
Enrollment
Unknown
Registered
2009-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2009-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Ischemia

Brief summary

In this study, patients were divided into 3 group with 35 cases including: 1.oxygen 2.enalapril 3.control. In the beginning of the study, best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), and optical coherence tomography (OCT) were measured. Patients in the oxygen group were given oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month. In the enalapril group, patients were given enalapril 5 mg every night and placebo was given for the patients in third group. At the end of first month the patients' vision was checked again and at the the end of the third month the first physical examinations were performed. In the first group, arterial blood gas (ABG) was taken before and after oxygen therapy as well.

Interventions

DRUGenalapril

enalapril 5 mg every night

OTHERoxygen

oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month

DRUGplacebo

Sponsors

Shahid Beheshti University of Medical Sciences
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Patients diagnosed with diabetic macular ischemia

Exclusion criteria

* HTN \> 1140/90 or HTN controlled by ACE inhibitors * FBS \> 200 * Severe anemia, COPD, cataract, HRPDR and diffuse macular edema

Countries

Iran

Contacts

Primary ContactMasoud Soheilian, MD
labbafi@hotmail.com+982122585952

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026